ClearNote Health Raises $52 Million in Series D Funding
ClearNote Health, a company dedicated to advancing early cancer detection through blood signal analysis, has successfully raised $52 million in its latest Series D funding round, announced on May 27, 2026. The company is led by CEO Dave Mullarkey, who is at the forefront of their mission to transform cancer management.
Innovative Approach to Cancer Detection
ClearNote Health focuses on the early detection of cancer by identifying signals in the blood. This approach aims to manage cancer more effectively by catching it at an earlier, more treatable stage. The company’s technology provides a non-invasive method to detect cancer, aiming to improve patient outcomes significantly.
Details of the Funding Round
The Series D round brought in a total of $52 million. While the specific investors were not disclosed, the infusion of capital reflects confidence in ClearNote Health’s innovative approach and technological advancements.
Use of Funds
While specific uses of the new funds were not detailed, companies in this sector typically allocate resources to enhance their technology, expand their market presence, and potentially increase their workforce to support growth. ClearNote Health is likely to focus on further developing its detection technology and expanding its reach in the healthcare market.
Leadership and Vision
CEO Dave Mullarkey continues to lead ClearNote Health with a vision of improving cancer management through early detection. Under his leadership, the company aims to advance its technology and broaden its impact in the healthcare industry.
ClearNote Health’s latest funding round marks a significant step in its journey to revolutionize cancer detection and improve patient care through innovative technology.